Related Experiment Video
Updated: Aug 30, 2026

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
Long-term outcome of hepatitis C infection after bone marrow transplantation
Régis Peffault de Latour1, Vincent Lévy, Tarik Asselah
1Service d'Hématologie-Greffe de Moelle, the Université Paris VII, Paris, France.
Insights
Hepatitis C virus (HCV) infection can lead to cirrhosis in long-term transplant survivors, occurring much faster than in non-transplant patients. Early detection and treatment are crucial for these patients.
Area of Science:
- Hepatology
- Transplantation Medicine
- Virology
Background:
- Chronic hepatitis C is often asymptomatic post-transplant.
- Advanced liver disease progression is considered rare after 10 years.
Purpose of the Study:
- To analyze the incidence and risk factors for cirrhosis in hematopoietic stem cell transplant (HSCT) recipients with HCV.
- To compare cirrhosis risk in HSCT recipients versus non-transplant controls.
Main Methods:
- Retrospective study of 96 HCV-infected patients post-allogeneic HSCT (1973-1995).
- Comparison with 158 HCV-infected non-transplant controls.
- Analysis of cumulative incidence, risk factors, and time to cirrhosis.
Main Results:
- 11% and 24% cumulative incidence of cirrhosis at 15 and 20 years post-HSCT.
- Extrahepatic HCV manifestations and HCV genotype 3 were significant risk factors.
- Median time to cirrhosis was 18 years in HSCT recipients vs. 40 years in controls.
- Significantly higher risk of cirrhosis in HSCT recipients (P=.0008).
Conclusions:
- Approximately 25% of long-term HSCT survivors with HCV develop cirrhosis.
- Cirrhosis develops more rapidly in HSCT recipients than in non-transplant patients.
- Systematic HCV detection, liver biopsy, and intervention are recommended for long-term HSCT recipients.
Abstract:
Chronic hepatitis C is often asymptomatic, at least during the first decade following hematopoietic stem cell transplantation. Progression to advanced liver disease or cirrhosis in patients surviving more than 10 years is currently thought to be rare. Among 1078 patients who underwent an allogeneic transplantation between January 1973 and January 1995, 96 patients infected by hepatitis C virus (HCV) during the transplantation period were studied. Cumulative incidence and analysis of risk factors for cirrhosis were analyzed, and the rate and risk of cirrhosis in transplant recipients were compared with those of 158 HCV-infected controls who did not receive transplants. At a median follow-up of 15.7 years, 15 patients developed biopsy-proven cirrhosis, leading to a cumulative incidence of cirrhosis of 11% and 24% at 15 and 20 years, respectively. By multivariate analysis, extrahepatic HCV manifestations and HCV genotype 3 were associated with risk of cirrhosis. The median time to cirrhosis in transplant recipients was 18 years as compared with 40 years in the control population. The risk of cirrhosis in transplant recipients relative to controls was significantly higher by multivariate analysis (P =.0008). Roughly a quarter of long-term HCV-infected survivors with transplants progressed to cirrhosis that is much more rapid than in patients without transplants. Systematic detection of HCV infection, liver biopsy, and therapeutic intervention are therefore warranted in long-term marrow transplant recipients.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Hepatitis